Palisade Bio
PALI
18 hedge funds and large institutions have $930K invested in Palisade Bio in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.01% less ownership
Funds ownership: 0.01% → 0.01% (-0.01%)
14% less funds holding
Funds holding: 21 → 18 (-3)
45% less capital invested
Capital invested by funds: $1.7M → $930K (-$765K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$75.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$21.8K |
| 4 |
Jane Street
New York
|
+$14.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$434K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$88.1K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$68K |
| 4 |
Renaissance Technologies
New York
|
-$64.7K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$37K |
PALI Hedge Fund Activity: Q1 2022 in Review
18 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2022, worth a combined $930K — down 45% from $1.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PALI and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $75.2K. The largest seller was Altium Capital Management, exiting entirely with an estimated $434K sold.
- 18 institutional investors held Palisade Bio (PALI) as of Q1 2022, down from 21 in Q4 2021.
- Funds reported $930K of Palisade Bio stock for Q1 2022, down 45% quarter-over-quarter.
- 3 funds opened new Palisade Bio positions in Q1 2022 and 6 closed out, a net change of -3 holders.
- The largest Palisade Bio buyer in Q1 2022 was Citadel Advisors, an estimated $75.2K added.
- The largest Palisade Bio seller in Q1 2022 was Altium Capital Management, an estimated $434K sold.
Based on aggregated 13F filings for Q1 2022.